Boston, Massachusetts--(Newsfile Corp. - October 21, 2021) - Block & Leviton is investigating Novavax Inc. (NASDAQ: NVAX) for potential securities law violations. Investors who have lost money in their Novavax Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/nvax.
What is this all about?
On October 19, 2021, after the market closed, Politico published an article, titled "'They Rushed the Process': Vaccine Maker's woes hamper global inoculation campaign", alleging manufacturing and purity problems in Novavax's process to produce COVID-19 vaccinations for COVAX, an international consortium working to provide two billion doses to middle and low income countries. Previously, the U.S. government invested $1.6B in Novavax in 2020, the most devoted to any vaccine manufacturer at the time.
On this news shares of Novavax fell over 20% in premarket trading on October 20, 2021.
Who is eligible?
Anyone who purchased Novavax Inc. stock and has lost money may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What is Block & Leviton doing?
Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.
What should you do next?
Why should you contact Block & Leviton?
Many law firms have issued releases about this matter; most of those firms do not actually litigate securities class actions. Block & Leviton is a law firm that actually litigates cases. We are dedicated to obtaining significant recoveries on behalf of defrauded investors through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email firstname.lastname@example.org with any questions.
This notice may constitute attorney advertising.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100463